A report issued by the university group sugar program (University Group Diabetes Program) In 1970 to increase the number of deaths due to heart disease in diabetics who are treated with a drug Altolbyautamad compared with those patients who were treated by injecting insulin.
There is still a contradiction to this day about the validity of this conclusion due to the presence of notes on how to design the study.
Thus, the relationship between the death of patients resulting from heart disease and drugs sulfonylureas did not prove clear and strong evidence.
For this reason, the sulfonylureas drugs still to this day are widely used for the treatment of patients with type II diabetes.
However in 1984 committed the Department of Nutrition and Drug Administration (FDA) Manufacturers of drugs sulfonylureas should be written warning about the possibility of increased risk of death due to heart disease as a result of the use of these drugs.
There is still a contradiction to this day about the validity of this conclusion due to the presence of notes on how to design the study.
Thus, the relationship between the death of patients resulting from heart disease and drugs sulfonylureas did not prove clear and strong evidence.
For this reason, the sulfonylureas drugs still to this day are widely used for the treatment of patients with type II diabetes.
However in 1984 committed the Department of Nutrition and Drug Administration (FDA) Manufacturers of drugs sulfonylureas should be written warning about the possibility of increased risk of death due to heart disease as a result of the use of these drugs.
Labels
sulfonylureas